| MADRIGAL PHARMACEUTICALS |
| USA |
| Gesundheit |
| US5588681057 / A2APCZ |
| YDO1 (Frankfurt) / MDGL (NASDAQ) |
| FRA:YDO1, ETR:YDO1, YDO1:GR, NASDAQ:MDGL |
| - |
| https://www.madrigalpharm.. |
|
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and relat..
>Volltext.. |
| 10529.63 Mio. EUR |
| 9984.11 Mio. EUR |
| 830.28 Mio. EUR |
| -258.67 Mio. EUR |
| -249.74 Mio. EUR |
| -11.14 EUR |
| 301.16 Mio. EUR |
| 176.54 Mio. EUR |
| -164.21 Mio. EUR |
| 3.19 |
| 368.95% |
| 45.46% |
| - |
| - |
| - |
| MADRIGAL |
| 05.04.26 |
|